Methamphetamine in Japan: the Consequences of Methamphetamine Abuse As a Function of Route of Administration
Overview
Authors
Affiliations
Aims: To determine differences in life backgrounds and clinical features between methamphetamine (MAP) smokers and injectors in Japan.
Setting: Out-patient clinic at a psychiatric centre.
Participants: Among 451 MAP abusers undergoing initial assessments, 116 subjects whom the first author had directly interviewed and treated were studied.
Design And Procedures: In this study, life backgrounds, clinical features and psychiatric symptoms were compared between three subgroups: 42 (36.2%) in group S (smoking only); 57 (49.1%) in group I (injection only); and 17 (14.7%) in group SI (initially smoking, later injecting).
Findings: Group I more often had parental absence (P < 0.001), a family history of alcoholism (P < 0.05), limited education (P < 0.001), or a criminal record (P < 0.001) than patients in the other two groups. Group S had the most cannabis use (P < 0.01), while group I had the most volatile solvents use (P < 0.01). Group S experienced their first psychotic episode sooner after first MAP use (P < 0.01), but showed fewer auditory hallucinations at initial assessment than patients in other groups (P < 0.001). Group SI was intermediate between groups S and I in life background, clinical features and psychotic symptoms, while they had lost control of their drug use most frequently (P < 0.02).
Conclusions: In Japan, MAP smokers have different life backgrounds from injectors. Smoking MAP does not appear to be a safer route as regards losing control of MAP use and inducing psychosis than injection.
Mahjoob M, Maleki A, Askarizadeh F, Heydarian S, Rakhshandadi T Int Ophthalmol. 2022; 42(7):2055-2062.
PMID: 35188605 DOI: 10.1007/s10792-021-02200-6.
McKetin R, Sutherland R, Peacock A, Farrell M, Degenhardt L Drug Alcohol Rev. 2021; 40(7):1256-1265.
PMID: 34365687 PMC: 9292494. DOI: 10.1111/dar.13364.
Matsumoto T, Kawabata T, Okita K, Tanibuchi Y, Funada D, Murakami M Neuropsychopharmacol Rep. 2020; 40(4):332-341.
PMID: 32896111 PMC: 7722680. DOI: 10.1002/npr2.12133.
Spivak B, Shepherd S, Borschmann R, Kinner S, Ogloff J, Hachtel H PLoS One. 2020; 15(5):e0229389.
PMID: 32469882 PMC: 7259510. DOI: 10.1371/journal.pone.0229389.
A Review of Risk Factors for Methamphetamine-Related Psychiatric Symptoms.
Chang X, Sun Y, Zhang Y, Muhai J, Lu L, Shi J Front Psychiatry. 2018; 9:603.
PMID: 30519197 PMC: 6251327. DOI: 10.3389/fpsyt.2018.00603.